iiinova — where your digital self keeps evolving

Anuja Java @anujajava.bsky.social · 21/09/2025

We're proudly supporting BrainShield, a student-led initiative making a real impact in our community by providing high-quality helmets to underfunded schools!! 💥 So far: $3,870 raised; 30 helmets donated; 65 amazing donors 🙏🙏 to everyone who’s supported! 💛 Join us: www.gofundme.com/f/helmets-fo...

gofundme.com

Protect Young Athletes: Helmet Donations to Schools, organized by BrainShield

Every child deserves to play the sport they love—safely. But currently… BrainShield needs your support for Protect Young Athletes: Helmet Donations to Schools

Anuja Java @anujajava.bsky.social · 02/05/2025

Faculty dinner @kidneycon.bsky.social! For those who missed: Topics covered 😉 Metabolic changes when Emperor Penguins molt How a lion’s kidney handles protein load after it eats a kudu Best baseball movies Kidney disease in athletes Genetically engineered crops Politics & Academia

030

Absolutely Taylor! I am with you on the aspect of patient voice. Will review the points in the article. We were looking at it from purely a scientific perspective since there’s a lot of discrepancy in the literature that has affected patient care & research in the field.

For that reason, the proposal was not to remove the name aHUS altogether. I think the physicians, patients and pharma need to come together as a next step to make sure everyone’s interests are aligned without compromising scientific advancement.

However I also see how this can be from a pt’s perspective when they have been diagnosed with a certain disease and now unsure what to call it. Moreover, since the drugs are approved for “aHUS”, it has created some unrest.

With advancements in understanding of etiology & ongoing understanding of the role of complement in various TMAs, it is important to move to a more etiology based classification so that appropriate & timely t/t is available to those who need it and avoid unnecessary treatment in patients who don’t.

Similarly, aHUS was a term given to a disease when it was not HUS. So it describes what it is NOT rather than what it IS.

110

Kidney Medicine Journal @kidneymed.bsky.social · 22/03/2025

From a scientific standpoint yes absolutely it is a step in the right direction. This is similar to why C3G is not called MPGN anymore. We still struggle with the term FSGS because we don’t understand the etiology fully. We have called diseases by what is seen on the biopsy.

231

Reposted by Anuja Java

Resistance-Based Muscle Therapy, Frailty, and Muscle Biopsy Findings in Kidney Transplant Candidates: A Clinical Trial

kidneymedicinejournal.org

Anuja Java @anujajava.bsky.social · 12/03/2025

Missed the NephJC:(:(. That’s a gorgeous mug!! Where did you get it?

110

Reposted by Anuja Java

NKF Nephrology Professionals @nkf-professionals.bsky.social · 11/03/2025

📢 SCM25 speakers! Let your network know you're presenting at SCM25 by sharing this graphic! Reshare with your session details and help spread the word. Tag @NKF_NephPros and use #NKFClinicals! 🔗 Learn more about SCM25: bit.ly/4hdIliU #Nephrology #MedEd

Anuja Java @anujajava.bsky.social · 11/03/2025

For all coffee lovers and for those who (like me) wonder why we still have daylight savings time 😊🤷‍♀️

American Journal of Kidney Diseases @ajkd.bsky.social · 10/03/2025

Reposted by Anuja Java

On the #AJKDBlog, revisit these interviews with: - Drs. Gaddy, Murugapandian, @amyaimei.bsky.social on viral nephropathy -Dr. Anuja Java discusses benefits of clinical genetic testing -Drs. Nair, Liu, @rasheedahall.bsky.social on frailty measurements bit.ly/3ztk4VV (FREE)

012

Anuja Java @anujajava.bsky.social · 09/03/2025

Fantastic overview of the latest in APOL-1 kidney disease by @genetickidneydoc.bsky.social @glomcon.org today!! Highlighted work from various labs @gbadegesinlab.bsky.social.

1114

Reposted by Anuja Java

American Journal of Kidney Diseases @ajkd.bsky.social · 24/02/2025

Counting down the Top Ten #NephMadness region posts from 2020-2024: 5️⃣ Thrombotic Microangiopathy Region (2023) bit.ly/3ERRvV2 Expert: @anuja_java Writer: @viral_nephro @AkbarNouman Exec: @KidneyWars @Maximal_Change Teams: Primary TMA vs Secondary TMA

043

Anuja Java @anujajava.bsky.social · 20/02/2025

Nice piece and fully agree!!

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/02/2025

Reposted by Anuja Java

And her conclusion Excellent highly densely packed TMA info from @anujajava.bsky.social #NephSky #Isnwcn

141

Reposted by Anuja Java

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/02/2025

For primary/complement mediated - genetic testing and complement investigations (later often still research tools) @anujajava.bsky.social stresses *not* to ignore VUS #ISNWCN #NephSky

131

Anuja Java @anujajava.bsky.social · 08/02/2025

Thank you Swap!! It was so good to see you🤗. Hope to catch up again before WCN ends.

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/02/2025

Reposted by Anuja Java

Move from primary/secondary to etiology Nice framework for work up, more here www.sciencedirect.com/science/arti... #ISNWCN #NephSky

141

Reposted by Anuja Java

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/02/2025

Next up is @anujajava.bsky.social on all about TMAs in 15 minutes #ISNWCN #NephSky Look at the changing terminology Link: www.sciencedirect.com/science/arti...

1104

Reposted by Anuja Java

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/02/2025

Quite an eclectic mix of topics and excellent speaker lineup @anujajava.bsky.social @bhallaresearch.bsky.social Brad Rovin Sush Waikar Kelsie Bogyo #ISNWCN #NephSky

081

Anuja Java @anujajava.bsky.social · 03/02/2025

That’s a beautiful click!!

Anuja Java @anujajava.bsky.social · 01/02/2025

Thrilled to share our center’s >decade experience of post-txp TMA @kireports.bsky.social Retrospective study of 68 cases & 3467 controls. Details of each pt’s clinical course, genetic etiology & functional studies in supplement. www.sciencedirect.com/science/article/pii/S2468024925000518

sciencedirect.com

Thrombotic Microangiopathy after Kidney Transplantation: Insights into Genetic Etiology and Clinical Outcomes

Thrombotic microangiopathy (TMA), marked by small vessel thrombosis from endothelial injury, presents significant diagnostic and treatment challenges …

0216

Reposted by Anuja Java

WashU Nephrology @washunephrology.bsky.social · 28/01/2025

Please join us in welcoming Mahmoud M. Musa, MD, as @washunephrology.bsky.social's 2025 renal #transplant fellow. "I am deeply committed to advancing this field and contributing to better care for ESKD patients," says Dr. Musa. t.co/XlpjubQNhg

011

Anuja Java @anujajava.bsky.social · 27/01/2025

We used to do Bactrim lifelong after kidney txp in all pts until a few years ago but now stop after a year. But for someone who has had PJP, I would prefer to continue lifelong.

Anuja Java @anujajava.bsky.social · 26/01/2025

Thank you Liz 🥰 I also need to get Richard Burwick & Nardhy Gomez-Lopez here.

Anuja Java @anujajava.bsky.social · 22/01/2025

Of course we vaccinate and use prophylactic Abx with ecu.

110

Anuja Java @anujajava.bsky.social · 22/01/2025

Doesn’t concern me. If anything, it spares the MAC, so risk of infection potentially lower compared to other anti-C agents like Ecu which we use along with IS.

140

Reposted by Anuja Java

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 21/01/2025

Quite poignant - but fitting that the new 2025 @kdigo.org ADPKD guidelines begin with a dedication to the late Tess Harris www.kidney-international.org/article/S008... #NephSky #ADPKD #PROMs

Dedication: Tess (Teresa) Harris, MA, FCIM (1956–2024):
dedicated patient advocate in the fight against polycystic
kidney disease (PKD) - page 1

Dedication: Tess (Teresa) Harris, MA, FCIM (1956–2024):
dedicated patient advocate in the fight against polycystic
kidney disease (PKD) - page 2

0135

I think that’s a very interesting idea.

But you definitely got me thinking about this @cavanaughdo.bsky.social 😊

030

I am literally just thinking aloud here:).

This concept is similar to donor specific Abs after transplant. Presence of a DSA doesn’t always mean it’s going to cause AMR. So how aggressive do we need to be to get rid of the DSAs and below what titre do we feel comfortable. Ultimately it is determined by clinical picture + functional testing.

140

I further worry about the balance between suppressing C3 enough to prevent convertase formation that prevents Nef formation but not enough to still have C3b for his opsonization & other protective function. I don’t know what that balance is and what is threshold for each.

230

I think this is imp because if you suppress C3 to prevent formation of a convertase, you may not have enough antigen presentation to B-cells to produce Nefs but not sure it would prevent production of naturally occurring C3 convertase Ab which you may still detect if you are using a binding assay.

So it’s important to first know what methodology is being used to test presence of Nefs because if one only uses binding assays, then it is not clear whether it is a benign C3 convertase IgG or a pathogenic nef. Therefore a functional assay that detects what that IgG is doing can determine it